Minhai COVID-19 vaccine

Minhai COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	KCONVAC (Chinese: 可维克; pinyin: Kěwéikè)
Routes of; administration	Intramuscular
Legal status
Legal status	Full list of Minhai vaccine authorizations;

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Clinical trials

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]

Children and adolescents trials

In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]

In September, KCONVAC started phase II trials with 480 participants in China.[5]

Authorizations

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]

References

Clinical trial number NCT04756323 for "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19) " at ClinicalTrials.gov
Clinical trial number NCT04758273 for "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)" at ClinicalTrials.gov
Clinical trial number NCT04852705 for "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)" at ClinicalTrials.gov
Clinical trial number NCT05003479 for "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
Clinical trial number NCT05003466 for "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
Reuters Staff (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021. {{cite news}}: |author= has generic name (help)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Clinical trial number NCT04756323 for "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19) " at ClinicalTrials.gov

[2] Clinical trial number NCT04758273 for "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)" at ClinicalTrials.gov

[3] Clinical trial number NCT04852705 for "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)" at ClinicalTrials.gov

[4] Clinical trial number NCT05003479 for "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov

[5] Clinical trial number NCT05003466 for "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov

[6] Reuters Staff (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021. {{cite news}}: |author= has generic name (help)